These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34838653)

  • 21. Optimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus.
    Desai S; Chan L; Handog E; Djojoseputro L; Lim J; Ling R; Nguyen H; Tam E; Tang J; Thng S; Tran H
    J Drugs Dermatol; 2023 Apr; 22(4):386-392. PubMed ID: 37026889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral tranexamic acid lightens refractory melasma.
    Tan AWM; Sen P; Chua SH; Goh BK
    Australas J Dermatol; 2017 Aug; 58(3):e105-e108. PubMed ID: 27173008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation.
    Ko D; Wang RF; Ozog D; Lim HW; Mohammad TF
    J Am Acad Dermatol; 2023 Feb; 88(2):291-320. PubMed ID: 35158001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interventions for melasma.
    Rajaratnam R; Halpern J; Salim A; Emmett C
    Cochrane Database Syst Rev; 2010 Jul; (7):CD003583. PubMed ID: 20614435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma.
    Sahu PJ; Singh AL; Kulkarni S; Madke B; Saoji V; Jawade S
    J Cosmet Dermatol; 2020 Jun; 19(6):1456-1462. PubMed ID: 32346962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral tranexamic acid, hydroquinone 4% and low-fluence 1064 nm Q-switched Nd:YAG laser for mixed melasma: Clinical and dermoscopic evaluation.
    Elkamshoushi AM; Romisy D; Omar SS
    J Cosmet Dermatol; 2022 Feb; 21(2):657-668. PubMed ID: 33826785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of tranexamic acid 5% cream vs hydroquinone 4% cream in treating melasma: A split-face comparative clinical, histopathological, and antera 3D camera study.
    El-Husseiny R; Rakha N; Sallam M
    Dermatol Ther; 2020 Nov; 33(6):e14240. PubMed ID: 32856757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microneedling as an adjuvant to topical therapies for melasma: A systematic review and meta-analysis.
    Bailey AJM; Li HO; Tan MG; Cheng W; Dover JS
    J Am Acad Dermatol; 2022 Apr; 86(4):797-810. PubMed ID: 33857549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study between oral tranexamic acid versus oral tranexamic acid and Q-switched Nd-YAG laser in melasma treatment: a clinical and dermoscopic evaluation.
    Agamia N; Apalla Z; Salem W; Abdallah W
    J Dermatolog Treat; 2021 Nov; 32(7):819-826. PubMed ID: 31908179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tranexamic Acid in the Treatment of Melasma: A Review of the Literature.
    Perper M; Eber AE; Fayne R; Verne SH; Magno RJ; Cervantes J; ALharbi M; ALOmair I; Alfuraih A; Nouri K
    Am J Clin Dermatol; 2017 Jun; 18(3):373-381. PubMed ID: 28283893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of energy-based devices combination therapy for melasma.
    Iranmanesh B; Khalili M; Mohammadi S; Amiri R; Aflatoonian M
    Dermatol Ther; 2021 May; 34(3):e14927. PubMed ID: 33665885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A split face comparative study between intradermal tranexamic acid and Erbium-YAG laser in treatment of melasma.
    Otb S; Shaarawy E; Sadek A; Abdallah N; Agamia N; Soliman M; Tawfik AA
    J Dermatolog Treat; 2022 Feb; 33(1):555-559. PubMed ID: 32420770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Future therapies in melasma: What lies ahead?
    Sarkar R; Bansal A; Ailawadi P
    Indian J Dermatol Venereol Leprol; 2020; 86(1):8-17. PubMed ID: 31793496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of melasma using a combination of microdermabrasion and Q-switched Nd:YAG lasers.
    Kauvar AN
    Lasers Surg Med; 2012 Feb; 44(2):117-24. PubMed ID: 22334295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of mesotherapy in the treatment of melasma: A review article.
    Khalili M; Amiri R; Iranmanesh B; Zartab H; Aflatoonian M
    J Cosmet Dermatol; 2022 Jan; 21(1):118-129. PubMed ID: 34846788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of microneedling plus topical 4% tranexamic acid solution vs 4% hydroquinone in the treatment of melasma: A single-blind randomized clinical trial.
    Shamsi Meymandi S; Mozayyeni A; Shamsi Meymandi M; Aflatoonian M
    J Cosmet Dermatol; 2020 Nov; 19(11):2906-2911. PubMed ID: 32406162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial.
    Saki N; Darayesh M; Heiran A
    J Dermatolog Treat; 2018 Jun; 29(4):405-410. PubMed ID: 29027510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of oral tranexamic acid as a novel treatment for melasma with a high benefit-risk ratio.
    Simpson J; Peng L; Ting W
    J Cosmet Dermatol; 2022 Nov; 21(11):6393-6399. PubMed ID: 35972476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral tranexamic acid for the treatment of melasma.
    Karn D; Kc S; Amatya A; Razouria EA; Timalsina M
    Kathmandu Univ Med J (KUMJ); 2012; 10(40):40-3. PubMed ID: 23575051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melasma: A Step-by-Step Approach Towards a Multimodal Combination Therapy.
    Philipp-Dormston WG
    Clin Cosmet Investig Dermatol; 2024; 17():1203-1216. PubMed ID: 38800358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.